These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21696249)

  • 1. Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: a case report.
    Begini P; Cox MC; Angeletti S; Gigante E; Baccini F; Di Fonzo M; Delle Fave G; Marignani M
    Scand J Infect Dis; 2011 Sep; 43(9):750-2. PubMed ID: 21696249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.
    Li HR; Huang JJ; Guo HQ; Zhang X; Xie Y; Zhu HL; Zhai LZ; Pu XX; Huang Y; Guo CC; Lin TY
    J Viral Hepat; 2011 Dec; 18(12):877-83. PubMed ID: 21054683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients].
    Yao GB; Ren H; Xu DZ; Zhou XQ; Jia JD; Wang YM; Chen CW
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):881-6. PubMed ID: 20038326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B.
    Wong VW; Wong GL; Yiu KK; Chim AM; Chu SH; Chan HY; Sung JJ; Chan HL
    J Hepatol; 2011 Feb; 54(2):236-42. PubMed ID: 21030105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
    Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine.
    Rago A; Ridola L; Lichtner M; Mecarocci S; Marocco R; Cenfra N; Belvisi V; Mastroianni CM; Cimino G
    J Antimicrob Chemother; 2012 Feb; 67(2):510-1. PubMed ID: 22110085
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
    Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
    Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
    LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.
    Babino G; Esposito M; Mazzotta A; Chimenti S; Giunta A
    Acta Derm Venereol; 2013 May; 93(3):373-4. PubMed ID: 23147755
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
    Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New advances in the treatment of chronic hepatitis B: position of entecavir].
    Olaso V
    Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.